Novartis: Iron Overload trials

The registry lists 38 Iron Overload studies with Novartis as lead sponsor. 0 are open to participants now and 23 have results posted.

Phase 1 2Phase 2 18Phase 3 4Phase 4 12No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional HemosiderosisCompletedNCT03372083Phase 4Results posted
• Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)TerminatedNCT03203850Phase 2Results posted
• Extended Evaluation of Deferasirox Film-coated Tablet (FCT) FormulationCompletedNCT02720536Phase 3Results posted
• Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron OverloadCompletedNCT02435212Phase 2Results posted
• Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)CompletedNCT02125877Phase 2Results posted
• An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)CompletedNCT01736540Phase 4Results posted
• Post Hematopoietic Stem Cell TransplantationCompletedNCT01610297Phase 4Results posted
• Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron OverloadTerminatedNCT01459718Phase 2Results posted
• Efficacy and Safety of Deferasirox in Combination With Deferoxamine Followed by Deferasirox Monotherapy in Severe Cardiac Iron OverloadCompletedNCT01254227Phase 2Results posted
• Safety and Efficacy of Deferasirox in Patients With Transfusion Dependent Iron Overload - a Non-comparative Extension StudyCompletedNCT01033747Phase 2/3Results posted
• Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension StudyCompletedNCT00873041Phase 2Results posted
• Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to FoodCompletedNCT00845871Phase 4Results posted
• Efficacy and Safety of Deferasirox in Patients With Chronic Anemia and Transfusional HemosiderosisCompletedNCT00631163Phase 2Results posted
• Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron OverloadCompletedNCT00600938Phase 2Results posted
• Cardiac T2* in Beta-thalassemia Patients on Deferasirox TreatmentCompletedNCT00447694Phase 2Results posted
• Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary HemochromatosisCompletedNCT00395629Phase 1/2Results posted
• A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.CompletedNCT00390858Phase 2Results posted
• Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia PatientsCompletedNCT00303329Phase 2Results posted
• Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)CompletedNCT00171301Phase 4Results posted
• An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron OverloadCompletedNCT00171210Phase 3Results posted
• Study for the Treatment of Transfusional Iron Overload in Myelodysplastic PatientsCompletedNCT00117507Phase 4Results posted
• Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease PatientsCompletedNCT00110617Phase 2Results posted
• Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic PatientsCompletedNCT00110266Phase 2Results posted
• Survey to Assess Physicians' Knowledge of Exjade Posology and Biological Monitoring Recommendations as Described in the Educational MaterialsCompletedNCT06215287
• Study to Assess Iron Chelation Therapy in Patients With Chronic Iron OverloadCompletedNCT05440487
• Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic AnemiaCompletedNCT01546415Phase 4
• Observation of Patients With Transfusional Hemosiderosis Treatment With DeferasiroxCompletedNCT01394029
• Open-Label Single-Arm Pilot Study in Adult Allogeneic Hematopoietic Stem Cell Transplant Recipients With Transfusional Iron OverloadCompletedNCT01335035Phase 4
• This Study Will Evaluate Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndromes (MDS), Thalassemia and Rare Anemia Types Having Transfusion-induced Iron Overload.CompletedNCT01250951Phase 4
• Efficacy and Safety of Oral Deferasirox (20 mg/kg/d) in Pts 3 to 6 Months After Allogeneic Hematopoietic Cell Transplantation Who Present With Iron OverloadCompletedNCT00654589Phase 4
• Evaluating the Efficacy of Deferasirox in Transfusion Dependent Chronic Anaemias (Myelodysplastic Syndrome, Beta-thalassaemia Patients) With Chronic Iron OverloadCompletedNCT00564941Phase 4
• Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron OverloadCompletedNCT00560820Phase 1
• Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron OverloadCompletedNCT00481143Phase 4
• ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With DeferasiroxCompletedNCT00466063
• Extension Study of Iron Chelation Therapy With Deferasirox in Patients With Transfusional Iron OverloadCompletedNCT00379483Phase 2
• Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood TransfusionsCompletedNCT00067080Phase 2
• Study of Deferasirox in Iron Overload From Beta-thalassemia Unable to be Treated With Deferoxamine or Chronic AnemiasCompletedNCT00061763Phase 2
• Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood TransfusionsCompletedNCT00061750Phase 3